The clinical significance of the anticentromere antibody

Marian H. Miller, G. O. Littlejohn, Ann Davidson, B. Jones, D. J. Topliss

Research output: Contribution to journalArticleResearchpeer-review

19 Citations (Scopus)

Abstract

To elucidate further the clinical significance of the anticentromere antibody (ACA), 32 Australian-born Caucasian patients with scleroderma (SD) or CREST (calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly and telangiectasia) were reclassified as ACA-positive (19 patients) or ACA-negative (13 patients). The clinical features of the two groups were compared. Mean disease duration was 11.7 years for the ACA-positive group and 1.1 years for the ACA-negative group. No ACA-positive patient had generalized skin SD, whereas all ACA-negative patients with disease duration greater than 6 months had moderate or severe proximal scleroderma. Only one ACA-positive patient had serious extra-oesophageal internal organ involvement, excluding primary biliary cirrhosis (three patients) which is itself associated with ACA. Three ACA-negative patients had serious extra-oesophageal internal organ involvement. No ACA-positive patient had been treated with penicillamine or captopril compared with 11 ACA-negative patients. Thus ACA appears to be a favourable prognostic indicator. Analysis of individual CREST manifestations in ACA-positive patients revealed that most had 'incomplete CREST', lacking one or two of the five features. The classification of SD patients as ACA-positive or ACA-negative is suggested.

Original languageEnglish
Pages (from-to)17-21
Number of pages5
JournalRheumatology
Volume26
Issue number1
DOIs
Publication statusPublished - 1 Feb 1987

Keywords

  • Anticentromere antibody
  • CREST
  • Scleroderma

Cite this

Miller, Marian H. ; Littlejohn, G. O. ; Davidson, Ann ; Jones, B. ; Topliss, D. J. / The clinical significance of the anticentromere antibody. In: Rheumatology. 1987 ; Vol. 26, No. 1. pp. 17-21.
@article{ccde0585bc554a5b9c4b80fb6c90b7e7,
title = "The clinical significance of the anticentromere antibody",
abstract = "To elucidate further the clinical significance of the anticentromere antibody (ACA), 32 Australian-born Caucasian patients with scleroderma (SD) or CREST (calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly and telangiectasia) were reclassified as ACA-positive (19 patients) or ACA-negative (13 patients). The clinical features of the two groups were compared. Mean disease duration was 11.7 years for the ACA-positive group and 1.1 years for the ACA-negative group. No ACA-positive patient had generalized skin SD, whereas all ACA-negative patients with disease duration greater than 6 months had moderate or severe proximal scleroderma. Only one ACA-positive patient had serious extra-oesophageal internal organ involvement, excluding primary biliary cirrhosis (three patients) which is itself associated with ACA. Three ACA-negative patients had serious extra-oesophageal internal organ involvement. No ACA-positive patient had been treated with penicillamine or captopril compared with 11 ACA-negative patients. Thus ACA appears to be a favourable prognostic indicator. Analysis of individual CREST manifestations in ACA-positive patients revealed that most had 'incomplete CREST', lacking one or two of the five features. The classification of SD patients as ACA-positive or ACA-negative is suggested.",
keywords = "Anticentromere antibody, CREST, Scleroderma",
author = "Miller, {Marian H.} and Littlejohn, {G. O.} and Ann Davidson and B. Jones and Topliss, {D. J.}",
year = "1987",
month = "2",
day = "1",
doi = "10.1093/rheumatology/26.1.17",
language = "English",
volume = "26",
pages = "17--21",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "1",

}

The clinical significance of the anticentromere antibody. / Miller, Marian H.; Littlejohn, G. O.; Davidson, Ann; Jones, B.; Topliss, D. J.

In: Rheumatology, Vol. 26, No. 1, 01.02.1987, p. 17-21.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The clinical significance of the anticentromere antibody

AU - Miller, Marian H.

AU - Littlejohn, G. O.

AU - Davidson, Ann

AU - Jones, B.

AU - Topliss, D. J.

PY - 1987/2/1

Y1 - 1987/2/1

N2 - To elucidate further the clinical significance of the anticentromere antibody (ACA), 32 Australian-born Caucasian patients with scleroderma (SD) or CREST (calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly and telangiectasia) were reclassified as ACA-positive (19 patients) or ACA-negative (13 patients). The clinical features of the two groups were compared. Mean disease duration was 11.7 years for the ACA-positive group and 1.1 years for the ACA-negative group. No ACA-positive patient had generalized skin SD, whereas all ACA-negative patients with disease duration greater than 6 months had moderate or severe proximal scleroderma. Only one ACA-positive patient had serious extra-oesophageal internal organ involvement, excluding primary biliary cirrhosis (three patients) which is itself associated with ACA. Three ACA-negative patients had serious extra-oesophageal internal organ involvement. No ACA-positive patient had been treated with penicillamine or captopril compared with 11 ACA-negative patients. Thus ACA appears to be a favourable prognostic indicator. Analysis of individual CREST manifestations in ACA-positive patients revealed that most had 'incomplete CREST', lacking one or two of the five features. The classification of SD patients as ACA-positive or ACA-negative is suggested.

AB - To elucidate further the clinical significance of the anticentromere antibody (ACA), 32 Australian-born Caucasian patients with scleroderma (SD) or CREST (calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly and telangiectasia) were reclassified as ACA-positive (19 patients) or ACA-negative (13 patients). The clinical features of the two groups were compared. Mean disease duration was 11.7 years for the ACA-positive group and 1.1 years for the ACA-negative group. No ACA-positive patient had generalized skin SD, whereas all ACA-negative patients with disease duration greater than 6 months had moderate or severe proximal scleroderma. Only one ACA-positive patient had serious extra-oesophageal internal organ involvement, excluding primary biliary cirrhosis (three patients) which is itself associated with ACA. Three ACA-negative patients had serious extra-oesophageal internal organ involvement. No ACA-positive patient had been treated with penicillamine or captopril compared with 11 ACA-negative patients. Thus ACA appears to be a favourable prognostic indicator. Analysis of individual CREST manifestations in ACA-positive patients revealed that most had 'incomplete CREST', lacking one or two of the five features. The classification of SD patients as ACA-positive or ACA-negative is suggested.

KW - Anticentromere antibody

KW - CREST

KW - Scleroderma

UR - http://www.scopus.com/inward/record.url?scp=0023105955&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/26.1.17

DO - 10.1093/rheumatology/26.1.17

M3 - Article

VL - 26

SP - 17

EP - 21

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 1

ER -